CroíValve Secures €4M in Additional Funding to Initiate Clinical Trials
HBAN investors have contributed towards €4 million in additional financing that has been secured by CroíValve, a high potential start-up (HPSU) supported by Enterprise Ireland developing a treatment for tricuspid regurgitation (TR). This is an issue affecting over half-a-million people every year in the US and EU alone, for which there is currently no suitable solution. The financing includes €2.5 million from the European Union under their Horizon 2020 SME Instrument grant and €1.5 million from Broadview Ventures and current investors (HBAN MedTech and Irrus Syndicates, Atlantic Bridge University Fund and SOS Ventures). The funding will accelerate the development of the company’s novel technology into First in Human studies.
Read Full Article from HBAN
Date: September 12, 2019
Provided By: https://www.hban.org/_shared/news/RSSNewsPage.aspx?Id=9